Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Maze Therapeutics (MAZE) FCF Margin (2024)

Maze Therapeutics has reported FCF Margin over the past 1 years, most recently at 918.96% for Q3 2024.

  • Quarterly FCF Margin changed N/A to 918.96% in Q3 2024 from the year-ago period, while the trailing twelve-month figure was 4265.0% through Jun 2025, changed N/A year-over-year, with the annual reading at 44.66% for FY2024, N/A changed from the prior year.
  • FCF Margin was 918.96% for Q3 2024 at Maze Therapeutics, down from 964.37% in the prior quarter.
  • Over five years, FCF Margin peaked at 964.37% in Q2 2024 and troughed at 918.96% in Q3 2024.